The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze)., and Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
In this video, Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone, New York, NY, mentions her two top abstracts in multiple myeloma (MM) from the ASH 2025 meeting. This first is the late-breaking abstract outlining the preliminary results from the inMMyCAR trial (NCT07075185), the first-in-human Phase I study of KLN-1010, a novel in vivo gene therapy
generating anti–BCMA CAR-T cells in patients with relapsed/refractory (R/R) myeloma. The second is the results of the MajesTEC-3 trial (NCT05083169), which compared teclistamab plus daratumumab (Tec-Dara) with standard of care regimens in R/R myeloma, yielding unprecedented results. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the two most amazing abstracts at ASH for me this year are both late-breaking abstracts. So there is one about the use of in vivo CAR T-cells and one about bispecific antibodies.
And I think the in vivo CAR T-cell one, although it’s still very early, the thought of being able to have a product that was off-the-shelf, that we could give to patients in the clinic with a good safety profile is incredible...
I think the two most amazing abstracts at ASH for me this year are both late-breaking abstracts. So there is one about the use of in vivo CAR T-cells and one about bispecific antibodies.
And I think the in vivo CAR T-cell one, although it’s still very early, the thought of being able to have a product that was off-the-shelf, that we could give to patients in the clinic with a good safety profile is incredible. And certainly the data we’ve seen shows that the patients are having really good response rates, CRs, but also with manageable toxicity. And also from a scientific side of things, I just think it’s really interesting the way that they’ve managed to manipulate the virus so that it only attacks the T-cells and leaves the rest of the cells alone in the body. So that’s one thing to kind of watch this space.
And then the second thing, bispecific antibodies in early lines of therapy. So the teclistamab data, looking at teclistamab with daratumumab in one to three prior treatments and comparing it to standard of care, which was daratumumab-pom-dex or daratumumab-velcade-dex. I think it’s probably the most amazing separation in curves we’ve ever seen in a myeloma study. And not only that, the actual kind of curve for the patients who are on the teclistamab-dara is not far off a straight line. So it really has the potential to make a huge difference for patients. As with anything, the devil’s in the detail. And one of the things that has come out is that we really need to be observant of infections and that we need to make sure that we’re giving both bacterial prophylaxis, PJP prophylaxis, but also IVIG because there is an increase in risk of infection and we really need to manage patients well because what we don’t want is patients who are in an amazing response having ongoing issues with infections.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
